Abstract
DNA vaccine has potential advantages exceeding the conventional vaccine. Recently, dendritic cells (DCs) attract attention as a target of DNA vaccine because DCs have a key role in initiating and controlling immune responses and are the most potent antigen-presenting cells (APCs). Currently, recombinant adenovirus (rAd) is used as the most efficient method for DC transduction. However, it is known that the DC transduction using rAd at a relatively high multiplicity of infection (MOI) interferes DC function and elicit strong immune response by presence of viral antigen. Therefore, the development of efficient non-viral gene vector is required to solve this problem.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
